NCT05443776

Brief Summary

A wide range of resorbable and non-resorbable membranes have been investigated over the last decades. Barrier membranes protect bone defects from ingrowth of soft tissue cells, provide mechanical stability of the defect area and allow bone progenitor cells to develop within a blood clot that is formed beneath the barrier membrane, taking a minimum of four to six weeks for periodontal tissues and 16-24 weeks for bone1,2.These membranes are utilized to reconstruct bone defects prior to implantation and to cover dehiscences and fenestrations around dental implants. When aiming to regenerate bone, resorbable or a non - resorbable membranes should be selected depending on location, size and defect area. However, until now the ideal membrane has not been described due to different opinions between authors3,4. Nevertheless, an ideal membrane should maintain its barrier function enough time for new bone formation, and if possible should be resorbable, so that a second surgical procedure for the explantation of the membrane would not be required, thus reducing the morbidity5. However, the use of a barrier membrane is a technique-sensitive procedure that is not free of complications. The main cause of Guided Bone Regeneration (GBR) failure is related to early or late exposure of the membrane, leading to contamination and infection of the biomaterial, irreversibly compromising bone regeneration4,6,7. Consequently, the inflammatory reaction of the surrounding soft tissues may require early removal of the membrane. Other complications, such as the onset of an abscess with purulent exudate, can also lead to a complete failure of GBR even without exposure of the membrane. It is thought necessary to perform this clinical study due to the lack of information present in the literature about the different types of membranes that exist nowadays, how they act in the human body with or without performing some type of regeneration and how our body acts towards them.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 15, 2019

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2021

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

March 18, 2022

Completed
4 months until next milestone

First Posted

Study publicly available on registry

July 5, 2022

Completed
Last Updated

July 5, 2022

Status Verified

June 1, 2022

Enrollment Period

1.9 years

First QC Date

March 18, 2022

Last Update Submit

June 29, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Grade of the biocompatibility of the biomaterials

    The grade of biocompatibility will be assessed by using histology tools, analyzing the type of cells present in the sample.

    Outcome will be measured once, after samples are collected and processed, 2-3 months after implantation.

  • Characteristics of the inmune response of the biomaterials in the host tissues

    The characteristics of the inmune response will be assessed by using histology tools, determining the presence of inflammatory cells such as macrophages.

    Outcome will be measured once, after samples are collected and processed, 2-3 months after implantation.

  • Rate of degradation of the biomaterials

    The rate of degradation of the biomaterials will be assessed by using histology tools, analyzing the amount of biomaterial present in the samples and comparing it to the amount that was implanted.

    Outcome will be measured once, after samples are collected and processed, 2-3 months after implantation.

Study Arms (6)

Study group biomaterial 1

EXPERIMENTAL
Other: Biomaterial implantation

Study group biomaterial 2

EXPERIMENTAL
Other: Biomaterial implantation

Study group biomaterial 3

EXPERIMENTAL
Other: Biomaterial implantation

Study group biomaterial 4

EXPERIMENTAL
Other: Biomaterial implantation

Study group biomaterial 5

EXPERIMENTAL
Other: Biomaterial implantation

Study group biomaterial 6

EXPERIMENTAL
Other: Biomaterial implantation

Interventions

Implant a approved biomaterial by European Regulatory Agencies

Study group biomaterial 1Study group biomaterial 2Study group biomaterial 3Study group biomaterial 4Study group biomaterial 5Study group biomaterial 6

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Overall, healthy patients that qualify for oral surgery (ASA I and II)
  • Older than 18 years old
  • Requiring extraction of 1-3 teeth (premolars or molars) that do not involve the aesthetic area
  • Stable post-extraction socket walls with at least 4 walls
  • Patient candidate to an early implant placement in the extraction area
  • Informed consent signed
  • Adequate oral hygiene: plaque index \< 25% before the surgery
  • Smoker of \<10 cigarettes per day
  • Able to follow the instructions and able to meet the follow-ups
  • Healthy or controlled periodontal disease

You may not qualify if:

  • Patients who not agree with informed consent
  • Untreated periodontal disease
  • Presence of dehiscence and/or fenestration at buccal plate of the extraction teeth
  • Patient who will need GBR or Block Regeneration
  • after the extraction
  • History of head and/or neck radiation
  • History of chemotherapy in the five years prior of the surgery
  • Non controlled Diabetes
  • Chronic corticoids or other medication that may influence healing and / or osseointegration
  • Smoker of \>10 cigars per day
  • Alcohol or other drugs abuse
  • Patient going under bisphosphonates treatment or taking

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UIC Barcelona

Barcelona, Spain

Location

Study Officials

  • Jordi Caball, DDS MSc PhD

    UIC Barcelona

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
FACTORIAL
Model Details: 6 different. products used, each compared between each other
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 18, 2022

First Posted

July 5, 2022

Study Start

September 15, 2019

Primary Completion

July 30, 2021

Study Completion

March 1, 2022

Last Updated

July 5, 2022

Record last verified: 2022-06

Data Sharing

IPD Sharing
Will not share

Locations